Table 4.
Univariate and multivariate analysis of prognostic factors in all evaluable patients (n=311)
| PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||
| Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | |
| Treatment Arm | 0.49 (0.37–0.63) |
<.0001 | 0.47 (0.36–0.61) |
<.0001 | 0.90 (0.64–1.27) |
0.56 | 0.88 (0.63–1.25) |
0.49 |
| MR (n=158) vs OBS (n=153) | ||||||||
| Tumor burden | 0.68 (0.51–0.89) |
0.005 | 0.79 (0.59–1.06) |
0.11 | 0.52 (0.35–0.77) |
0.0009 | 0.64 (0.43–0.96) |
0.03 |
| Low (n=111) vs. High (n=200) | ||||||||
| Histology | 0.99 (0.74–1.31) |
0.92 | 0.56 (0.39–0.80) |
0.001 | 0.56 (0.39–0.81) |
0.002 | ||
| Follicular (n=228) vs. Other (n=83) | ||||||||
| Residual disease | 0.63 (0.49–0.82) |
0.0005 | 0.71 (0.54–0.94) |
0.02 | 0.51 (0.36–0.73) |
0.0001 | 0.62 (0.42–0.90) |
0.01 |
| Minimal (n=175) vs. Gross (n=136) | ||||||||
| Response to CVP | 0.58 (0.39–0.85) |
0.005 | 0.67 (0.44–1.02) |
0.06 | 0.57 (0.33–0.98) |
0.04 | 0.78 (0.44–1.41) |
0.41 |
| CR (n=49) vs. Other (n=262) | ||||||||
| FLIPI | 1.05 (0.79–1.38) |
0.75 | 1.77 (1.24–2.52) |
0.001 | 1.75 (1.21–2.53) |
0.003 | ||
| High risk (n=95) vs. Other (n=216) | ||||||||
| Gender | 0.85 (0.66–1.11) |
0.23 | 0.65 (0.46–0.93) |
0.02 | 0.58 (0.40–0.83) |
0.003 | ||
| Female (n=140) vs. Male (n=171) | ||||||||
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval